Loxo Oncology, Inc. (LOXO) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2018 MRQ | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments, including: | 626,200 | 141,800 | 153,892 | 106,292 | |||
| Cash and cash equivalents | 142,025 | 30,376 | 68,177 | 43,930 | |||
| Short-term investments | 484,175 | 108,935 | 85,715 | 62,362 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 2,489 | ||||||
| Other undisclosed current assets | 155,607 | (6) | 2,752 | 1,484 | |||
| Total current assets: | 781,807 | 141,794 | 156,644 | 107,776 | |||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 912 | 248 | 88 | 12 | |||
| Long-term investments and receivables | 2,499 | 6,648 | |||||
| Long-term investments | 2,499 | 6,648 | |||||
| Deposits noncurrent assets | 23 | ||||||
| Other noncurrent assets | 723 | 771 | 726 | ||||
| Total noncurrent assets: | 1,635 | 3,518 | 814 | 6,683 | |||
| TOTAL ASSETS: | 783,442 | 145,312 | 157,458 | 114,459 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 26,533 | 15,144 | 2,853 | 1,787 | |||
| Accounts payable | 3,996 | 1,061 | 269 | 239 | |||
| Accrued liabilities | 22,537 | 14,083 | 2,584 | 1,548 | |||
| Deferred revenue and credits | ✕ | 195,037 | |||||
| Total current liabilities: | 221,570 | 15,144 | 2,853 | 1,787 | |||
| Noncurrent Liabilities | |||||||
| Liabilities, other than long-term debt | 183,662 | ||||||
| Deferred revenue and credits | ✕ | 183,662 | |||||
| Total noncurrent liabilities: | 183,662 | ||||||
| Total liabilities: | 405,232 | 15,144 | 2,853 | 1,787 | |||
| Equity | |||||||
| Equity, attributable to parent | 378,210 | 130,168 | 154,605 | 112,672 | |||
| Common stock | 3 | 2 | 2 | 2 | |||
| Additional paid in capital | 666,891 | 269,423 | 221,457 | 143,660 | |||
| Accumulated other comprehensive loss | (572) | (21) | (16) | (28) | |||
| Accumulated deficit | (288,112) | (139,236) | (66,838) | (30,962) | |||
| Total equity: | 378,210 | 130,168 | 154,605 | 112,672 | |||
| TOTAL LIABILITIES AND EQUITY: | 783,442 | 145,312 | 157,458 | 114,459 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 56 | |||||
| Gross profit: | 56 | |||||
| Operating expenses | (173,696) | (73,178) | (24,464) | (13,122) | ||
| Other undisclosed operating income (loss) | 21,300 | (56) | (7,568) | |||
| Operating loss: | (152,396) | (73,178) | (24,464) | (20,690) | ||
| Loss from continuing operations before equity method investments, income taxes: | (152,396) | (73,178) | (24,464) | (20,690) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 778 | (11,611) | 41,390 | |||
| Income (loss) from continuing operations: | (152,396) | (72,400) | (36,075) | 20,700 | ||
| Income (loss) before gain (loss) on sale of properties: | (152,396) | (72,400) | (36,075) | 20,700 | ||
| Other undisclosed net income | 3,520 | |||||
| Net income (loss): | (148,876) | (72,400) | (36,075) | 20,700 | ||
| Other undisclosed net income (loss) attributable to parent | 2 | 199 | (41,372) | |||
| Net loss attributable to parent: | (148,876) | (72,398) | (35,876) | (20,672) | ||
| Preferred stock dividends and other adjustments | (34) | |||||
| Net loss available to common stockholders, diluted: | (148,876) | (72,398) | (35,876) | (20,706) | ||
Comprehensive Income ($ in thousands)
| 9/30/2018 TTM | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (148,876) | (72,400) | (36,075) | 20,700 | ||
| Comprehensive income (loss): | (148,876) | (72,400) | (36,075) | 20,700 | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (551) | (3) | 211 | (41,400) | ||
| Comprehensive loss, net of tax, attributable to parent: | (149,427) | (72,403) | (35,864) | (20,700) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.